Search
Ascidian and Lilly signed a collaboration today to use Ascidian's RNA exon editing platform for monogenic kidney diseases, potentially worth up to $1.9 billion in milestones
Ascidian CEO Mike Ehlers tells us about the deal and discusses the technology and the potential benefits of it over DNA editing and other genetic medicine approaches.
Jun 3
Ascidian Therapeutics' CEO discusses today's collaboration with Roche on the company's RNA exon editing technology for neurological conditions
Mike Ehlers describes how this $42M upfront and up to $1.8B in potential milestones deal is focused on neurological conditions, how RNA...
Jun 18, 2024
The Science Behind the News: Ascidian Therapeutics' IND is cleared for an RNA exon editing program against Stargardt disease
Ascidian Interim President & CEO Mike Ehlers explains the scientific concept of RNA exon editing
Jan 29, 2024
.png){kind=logo}